Bioaffinity Technologies vs Lucid Diagnostics
Bioaffinity Technologies is the larger business, with $6.2m of revenue in fiscal 2025 against $4.7m for Lucid Diagnostics (1.3 times as much). Lucid Diagnostics grew faster (8.3% against -34.2%). Bioaffinity Technologies kept more of each dollar of sales as profit: a net margin of -242.0% against -1232.7%. Bioaffinity Technologies carries less debt relative to equity (2.0% against 219.5%).
| Latest fiscal year | Bioaffinity TechnologiesBIAF, 2025 | Lucid DiagnosticsLUCD, 2025 |
|---|---|---|
| Revenue | $6.2m | $4.7m |
| Revenue growth | -34.2% | 8.3% |
| Net income | −$14.9m | −$58.0m |
| Operating margin | -171.6% | -1054.8% |
| Net margin | -242.0% | -1232.7% |
| Return on equity | — | — |
| Free cash flow | −$9.4m | −$46.7m |
| Cash | $6.4m | — |
| Total debt | $146,474 | $24.0m |
| Debt to equity | 2.0% | 219.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 57 | 82 |
| Market value | $21.0m | $76.9m |
| Price vs our value range | — | — |
| Moat score | — | 17 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 0 sales |